Levels of angiogenesis markers in patients with different heart failure phenotypes

CARDIOVASCULAR THERAPY AND PREVENTION, Год журнала: 2022, Номер 21(3), С. 3230 - 3230

Опубликована: Март 6, 2022

Aim . To assess the relationship between levels of angiogenesis markers and various heart failure (HF) phenotypes in patients with class II-IV HF ischemic origin. Material methods. This cross-sectional cohort study was based on clinical departments National Medical Research Center for Therapy Preventive Medicine. The involved 180 aged 30-85 years origin as follows (n=90) without metabolic syndrome (MS). All included signed an informed consent to personal data processing, participation a trial blood biobanking. were divided into three groups: reduced ejection fraction (HFrEF) — left ventricular (LV) EF <40%, mildly (HFmrEF) LVEF from 40 49%, preserved (HFpEF) >49%. In addition standard paraclinical investigations, analyzed determination transforming growth factor β (TGF-β), vascular endothelial A (VEGF-A), pentraxin-3 (PTX-3). Statistical analysis performed using Microsoft Office Excel, STATISTICA 10.0 software packages (Statsoft, USA). Results Transthoracic echocardiography determined that 74 (41,1%) had <50%, while 71 (39,4%) <40%. For group HFpEF, there association increase TGF-β ≥7,2 ng/ml (p=0,011). threshold level PTX-3 ≥55 is associated development HFpEF (p=0,001). HFmrEF phenotype, values VEGF-A, determined, which did not reach significance level. However, upward trend VEGF-A >200 noted (p=0,052). HFrEF patients, value >195 (p=0,001) determined. Conclusion Thus, present work showed relevance PTX-3, additional assessing course. So, increased TGF-β, values. Determination these should be used improve efficiency diagnosis treatment phenotypes.

Язык: Английский

---

Contribution of polymorphism of genes of aldosterone synthetase CYP11B2 (C-344T), adrenergic receptors type 1 ADRB1 (Gly389Arg) and type 2 ADRB2 (Arg16Gly) to formation of different obesity phenotypes

Perm Medical Journal, Год журнала: 2022, Номер 39(2), С. 37 - 44

Опубликована: Май 10, 2022

Objective. To study the relationship of polymorphism genes aldosterone synthetase CYP11B2 (C-344T), adrenergic receptor type 1 ADRB1 (Gly389Arg) and 2 ADRB2 (Arg16Gly) with risk obesity. Materials methods. The involved 170 patients; mean age was 45.4 7.3 years. patients were divided into groups: group obese metabolic disorders in combination 1-2 degree hypertension complicated obesity (n = 90); 50 participants without (metabolically healthy obesity). control consisted 100 respondents. All surveyed persons underwent anthropometry general clinical studies according to recommendation for examination arterial hypertension. Total DNA isolated from venous whole blood samples by RT-PCR using DNA-Sorb-B kit. Results. It found that obesity, carriage TT genotype gene (C-344T) CG Gly389Arg prevailed comparison metabolically predominance GG revealed groups group. An association polymorphic position level low-density lipoprotein cholesterol, triglycerides, systolic pressure diastolic pressure, uric acid established. between promoter region glomerular filtration rate total cholesterol determined. Conclusions. Analysis (Gly389Arg), (Arg16Gly), variants can be used as an additional marker assess developing hypertension, disorders.

Язык: Английский

---

Arterial hypertension and metabolic syndrome in non-indigenous residents of the Far North

Russian Journal of Preventive Medicine, Год журнала: 2022, Номер 25(9), С. 46 - 46

Опубликована: Янв. 1, 2022

Метаболический синдром (МС) является предиктором большинства сердечно-сосудистых событий и поэтому остается актуальной проблемой медицины.

ЦЕЛЬ ИССЛЕДОВАНИЯ

Дать характеристику структуре МС по составляющим компонентам у некоренных лиц, постоянно проживающих в условиях Крайнего Севера, с артериальной гипертонией (АГ).

МАТЕРИАЛ И МЕТОДЫ

В период 2016—2019 гг. исследование включены 308 пациентов АГ МС, Севера (Ханты-Мансийский автономный округ — Югра). Мужчин было 142 (46,1%), женщин 166 (53,9%). По возрасту все пациенты разделены на две группы: 1-я группа 36—40 лет (n=150), 2-я 41—46 (n=158). степени представлены следующим образом: 1-й (n=91), 2-й (n=125), 3-й (n=92). настоящем исследовании для диагностики руководствовались Рекомендациями ведению больных метаболическим синдромом (2013).

РЕЗУЛЬТАТЫ

АГ, представлен комбинациями из 3, 4 5 элементов. При этом регистрируется 3-компонентный вариант тогда как особенно характерны 4-компонентный 5-компонентный варианты соответственно.

ЗАКЛЮЧЕНИЕ

Между ожирением определяется тесная патогенетическая связь. С одной стороны, ожирение пусковым механизмом развития другой вызывает снижение чувствительности периферических тканей к инсулину, что приводит развитию ожирения. Вероятность лиц избыточной массой тела 50% выше, чем нормальной тела. сочетается центральным типом ожирения, который обусловливает такие симптомы, инсулинорезистентность, нарушение толерантности глюкозе, дислипидемия.

Язык: Русский

---

Cardiovascular risk in a comorbid patient. A comparative analysis considering traditional risk factors

Russian Journal of Preventive Medicine, Год журнала: 2023, Номер 26(5), С. 52 - 52

Опубликована: Янв. 1, 2023

Язык: Английский

---

Effective strategies for prevention of cardiovascular complications in elderly patients with arterial hypertension and obesity (clinical example)

Medical alphabet, Год журнала: 2020, Номер 21, С. 10 - 18

Опубликована: Окт. 15, 2020

The frequency of arterial hypertension has a clear tendency to increase with age. presence obesity imposes additional difficulties on the choice antihypertensive therapy regimen due variety pathophysiological mechanisms raising blood pressure in patients combination and obesity. This article presents clinical case 68-year-old patient obesity, discusses comprehensive approach that includes diet, regular physical activity, cognitive training pharmacotherapy fixed amlodipine telmisartan imidazoline receptor agonist moxonidine. this is following reasons: ultra-prolonged action both drugs, which allows you control during day, including morning, when there greatest number cardiovascular events; organoprotective properties; improving carbohydrate metabolism; reducing risk diabetes; antiatherosclerotic properties. moxonidine need effective pressure, reduction activity sympathetic nervous system, because hypersympathicotonia one central pathogenetic for decrease resting heart rate less than 80 bpm (an independent factor complications hypertension). Dietary recommendations will help reduce body weight slow progression atherosclerosis, prevent development catastrophes, improve quality life. aim weight, functions risks. Cognitive function and, consequently, adherence treatment. After six weeks complex treatment, noted achievement target loss, improved mood, increased exercise tolerance, life, as well proteinuria, completely disappeared after another three months therapy.

Язык: Английский

---